RECEIVED CENTRAL FAX CENTER

APR 2 4 2006

U.S. Palent and Trademark Office; U.S. DePARTMENT OF COMMERCE U.S. Palent and Trademark Office; U.S. DePARTMENT OF COMMERCE Linder the Paperwork Reduction Act of 1995 ng persons are populated to respond to a collection of information unless it displays a valid OMS counted number.									
REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS				ation Numi	10/506,592				
			Flüng	Filing Date		September 3, 2004			
			First	First Named Inventor		Andrew David Morely			
			Art U	Art Unit		1626			
			Exam	Examiner Name		Nolan, Jason Michael			
			Alton	Attomisy Docket Number 100659			-1P US		
I hareby revoke all provious powers of attorney given in the above-identified application.									
A Power of Attorney is submitted herewith.									
OR									
x I hereby appoint the practitioners associated with the Customer Number: 44992									
Please change the correspondence address for the above-identified application to:									
The address associated with Customer Number: 44992									
Firm or Individual Name AstraZeneca Pharmaceuticals LP									
Address Global Intellectual Property 35 Gatehouse Drive									
City	Waltham								
Country	USA		State	MA		· · ·	Zip	02451	
	Telephone (781) 839-4000			Fax (781) 839-4121				1121	
l am the:									
Applicant/Inventor.									
Assignee of record of the ent re Interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) Is enclosed. (Form PTO/SB/96)									
SIGNATURE of Applicant or Assignee of Record									
Signature T. &									
Name Tracey Bryant									
Date	1	ANGART		-	Telephor			(0) 1625 513228	
NOTE: Signatures of all the inventors or tradignees of record of the endre interest of their representative(s) are required. Submit multiple forms it more than one algusture is required, see below.									
X *Total of 1 forms are submitted.									

PTO/SE/96 (09-04) Approved for use through 07/31/2008, OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1985, operands are required to respond to a collegion of information unless is displaye a valid CMB control number. STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner. Andrew David Morley Application No.: 10/506.592 Filed: September 3, 2004 INDOLE-AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORAYLASE INHIBITORS AstraZenoca AB (Name of Assig states that it is: | x | the assignee of the entire right, title, and interest; or 1. an assignee of less than the entire right, title and interest. 2. The extent (by percentage) of its ownership interest is in the patent application/patent identified above by virtue of either: An assignment from the impentor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel ____016412 , or for which a copy thereof is attached. OR A chain of title from the inventor(s), of the patent application/patent identified above, to the current B. assignee as shown bolow: 1. From: To: The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached. 2. From: The document was recorded in the United States Patent and Trademark Office at _ , or for which a copy thereof is attached. Reel 3. From: To: The document was recorded in the United States Patent and Trademark Office at , Framo _____, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (..e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302,08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. 13 VANUARY DEDG Tracey Bryant Telephone Number Printed or Tyr ed Name +44 (0) 1625 513228 Authorized Signer for Assignee Title: Patent Director, Oncolog / & Infection